Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasms by Site 1 Neoplasms 1 ESR1 Gene Mutation 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms, Male 1 Breast Diseases 1 Brain Neoplasms 1 Brain Diseases 1 Advanced ER+, HER2-Negative Breast Cancer 1 Advanced Breast Cancer 1

Interventions

exemestane 2 Letrozole 2 seviteronel 1 sargramostim 1 ribociclib 1 methyl N-acetylsibirosaminide 1 elacestrant 1 Trastuzumab 1 Tamoxifen 1 Suspensions 1 Receptor Protein-Tyrosine Kinases 1 Presenilin-1 1 Pemetrexed 1 Leuprolide 1 Injections 1 HER2 peptide (369-377) 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Goserelin 1 Fentanyl 1 Anastrozole 1 90Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Breast Neoplasms, Male × elacestrant × Clear all

NCT06492616 2026-05-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡